Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | AOC2 | O75106 | 5/20 | 0.50 |
| ▸ | MAOA | P21397 | 5/20 | 0.50 |
| ▸ | MAOB | P27338 | 5/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27730852 | 0.85 | HPGD (0.61) | HPGDTSHRAOC2MAOAMAOB | |
| SCHEMBL29974170 | 0.83 | HPGD (0.59) | HPGDTSHRAOC2MAOAMAOB | |
| SCHEMBL5847146 | 0.83 | HPGD (0.64) | HPGDTSHRAOC2MAOAMAOB | |
| SCHEMBL5109501 | 0.83 | HPGD (0.64) | HPGDTSHRAOC2MAOAMAOB | |
| SCHEMBL860446 | 0.83 | HPGD (0.59) | HPGDTSHRAOC2MAOAMAOB | |
| SCHEMBL1519327 | 0.83 | HPGD (0.64) | HPGDTSHRAOC2MAOAMAOB | |
| SCHEMBL2152568 | 0.81 | HPGD (0.58) | HPGDTSHRAOC2MAOAMAOB | |
| SCHEMBL2176045 | 0.81 | HPGD (0.58) | HPGDTSHRAOC2MAOAMAOB | |
| Hydrochloric Acid SCHEMBL11343820 | 0.81 | HPGD (0.62) | HPGDTSHRAOC2MAOAMAOB | |
| SCHEMBL24147440 | 0.81 | HPGD (0.54) | HPGDTSHRAOC2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973163-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7943770-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| EP-1740584-B9 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20090275568-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090270625-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090258893-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-15 | — | — | US | disclosed |
| US-7592453-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-22 | — | — | US | disclosed |
| EP-2080760-A1 | Fused quinoline derivative and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2009-07-22 | — | — | EP | disclosed |
| EP-1740584-B1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2008-12-03 | — | — | EP | disclosed |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275568-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TACR2, HRH3, HRH2 | HPGD 1635/4885TSHR 515/4885AOC2 1302/4885 |
| US-20090258893-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TACR2, HRH3, HRH2 | HPGD 1635/4885TSHR 515/4885AOC2 1302/4885 |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TACR2, HRH3, HRH2 | HPGD 1619/4885TSHR 496/4885AOC2 1346/4885 |
| US-20090270625-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TACR2, HRH3, HRH2 | HPGD 1708/4885TSHR 514/4885AOC2 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.